• Angela Fagerlin, Amanda J Dillard, Dylan M Smith, Brian J Zikmund-Fisher, Rosemarie Pitsch, Jennifer B McClure, Sarah Greene, Sharon Hensley Alford, Vijayan Nair, Daniel F Hayes, Cheryl Wiese, and Peter A Ubel.
• Ann Arbor VA HSR&D Center for Practice Management and Outcomes Research, Ann Arbor, MI, USA. fagerlin@umich.edu
• Breast Cancer Res. Treat. 2011 Jun 1; 127 (3): 681-8.

AbstractAlthough tamoxifen can prevent primary breast cancer, few women use it as a preventive measure. A second option, raloxifene, has recently been approved. The objective of the study was to determine women's interest in tamoxifen and raloxifene after reading a decision aid (DA) describing the risks and benefits of each medication. Women with 5-year risk of breast cancer ≥ 1.66 from two large health maintenance organizations were randomized to receive a DA versus usual care. After reading an on-line DA that discussed the risks and benefits of tamoxifen and raloxifene, women completed measures of risk perception, decisional conflict, behavioral intentions, and actual behavior related to tamoxifen and raloxifene. 3 months following the intervention, 8.1% of participants had looked for additional information about breast cancer prevention drugs, and 1.8% had talked to their doctor about tamoxifen and/or raloxifene. The majority, 54.7%, had decided to not take either drug, 0.5% had started raloxifene, and none had started tamoxifen. Participants were not particularly worried about taking tamoxifen or raloxifene and did not perceive significant benefits from taking these drugs. Over 50% did not perceive a change in their risk of getting breast cancer if they took tamoxifen or raloxifene. After reading a DA about tamoxifen and raloxifene, few women were interested in taking either breast cancer prevention drug.

19 keywords...

hide…